Acquisitions and License Agreements (Narrative) (Details) (USD $)	3 Months Ended									12 Months Ended				0 Months Ended	12 Months Ended	3 Months Ended	12 Months Ended				60 Months Ended	12 Months Ended		60 Months Ended	12 Months Ended		60 Months Ended		0 Months Ended
	Sep. 27, 2013	Jun. 28, 2013		Mar. 29, 2013	Dec. 28, 2012	Sep. 28, 2012	Jun. 29, 2012	Mar. 30, 2012	Dec. 30, 2011	Sep. 27, 2013	Sep. 28, 2012	Sep. 30, 2011	Oct. 01, 2012 CNS Therapeutics, Inc.	Oct. 01, 2012 Specialty Pharmaceuticals CNS Therapeutics, Inc.	Sep. 27, 2013 Specialty Pharmaceuticals CNS Therapeutics, Inc.	Sep. 28, 2012 Specialty Pharmaceuticals Roxicodone	Sep. 27, 2013 Specialty Pharmaceuticals Roxicodone	Sep. 27, 2013 Specialty Pharmaceuticals Exalgo Licensing Agreements	Sep. 28, 2012 Specialty Pharmaceuticals Exalgo Licensing Agreements	Sep. 30, 2011 Specialty Pharmaceuticals Exalgo Licensing Agreements	Sep. 27, 2013 Specialty Pharmaceuticals Exalgo Licensing Agreements	Sep. 27, 2013 Specialty Pharmaceuticals Depomed Licensing Agreements	Sep. 30, 2011 Specialty Pharmaceuticals Depomed Licensing Agreements	Sep. 27, 2013 Specialty Pharmaceuticals Depomed Licensing Agreements	Sep. 27, 2013 Specialty Pharmaceuticals Pennsaid Licensing Agreements	Sep. 28, 2012 Specialty Pharmaceuticals Pennsaid Licensing Agreements	Sep. 27, 2013 Specialty Pharmaceuticals Pennsaid Licensing Agreements	Sep. 27, 2013 Finite-Lived Intangible Assets Specialty Pharmaceuticals Exalgo Licensing Agreements	Oct. 01, 2012 In-process research and development Specialty Pharmaceuticals CNS Therapeutics, Inc.
Business Acquisition [Line Items]
Total consideration														$ 95,000,000
Cash payment, net of cash acquired										88,100,000	0	0		88,100,000
Plus: cash assumed in acquisition														3,600,000
Contingent consideration													6,900,000	6,900,000
Contingent consideration, potential maximum													9,000,000	9,000,000
Estimated cost to complete in-process research																													18,000,000
Assumptions used calculating in-process research and development, discount rate														35.00%
Net sales	545,200,000	570,000,000	[1]	585,300,000	504,000,000	513,100,000	516,300,000	523,100,000	503,700,000	2,204,500,000	2,056,200,000	2,021,800,000			29,200,000		8,400,000
Payment to acquire intangible assets										0	13,200,000	0				13,200,000
Contingent payment, maximum additional amount																		73,000,000				64,000,000			120,000,000
Milestone payments																					65,000,000	5,000,000	0	7,000,000			15,000,000	55,000,000
Royalties paid																		$ 24,000,000	$ 16,100,000	$ 5,500,000				$ 0	$ 3,900,000	$ 7,500,000

[1] Operations in the third quarter of fiscal 2013 were impacted by the Separation.